{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:42Z","timestamp":1791650562467,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japan Society for the Promotion of Science: JSPS","award":["22K09512"],"award-info":[{"award-number":["22K09512"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Enfortumab vedotin (EV) is a novel antibody\u2013drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in efficacy of EV after each ICIs and prognostic factors are not well known. We aimed to compare the efficacy of EV in patients with metastatic UC who were treated with avelumab or pembrolizumab and to identify the prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The records of 100 patients with advanced metastatic UC who received EV after the administration of either avelumab or pembrolizumab were retrospectively collected from five academic hospitals in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median follow-up period was 6.7\u00a0months. The median overall survival (OS) and progression-free survival (PFS) in the EV after avelumab\/pembrolizumab group were not reached\/14.7\u00a0months (p\u2009=\u20090.17) and 10.4\/5.2\u00a0months (p\u2009=\u20090.039), respectively. The objective response rates (ORR) were 66.6% and 46.8% in EV after avelumab and EV after pembrolizumab groups, respectively (p\u2009=\u20090.14). Multivariate analysis identified histological variants, liver metastasis, low serum albumin levels, and high serum CRP level as significant poor prognostic factors. The median OS and PFS of cachexia patients with both low serum albumin levels and high serum CRP levels were 6.0\u00a0months and 0.93\u00a0months, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PFS was superior in patients treated with EV after avelumab to EV after pembrolizumab. However, OS showed no significant difference between the two groups. Because the prognosis of patients with cachexia is extremely poor, the initiation of EV should be discussed in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-024-05717-2","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T01:02:01Z","timestamp":1712624521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan"],"prefix":"10.1007","volume":"150","author":[{"given":"Yosuke","family":"Hirasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo","family":"Uchimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Shiroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"issue":"2","key":"5717_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.clgc.2021.11.010","volume":"20","author":"A Abuhelwa","year":"2022","unstructured":"Abuhelwa A, Bellmunt J, Kichenadasse G, McKinnon R, Rowland A, Sorich MJ et al (2022) Enhanced bellmunt risk score for survival prediction in urothelial carcinoma treated with immunotherapy. Clin Genitourin Cancer 20(2):132\u2013138","journal-title":"Clin Genitourin Cancer"},{"key":"5717_CR2","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"J Bellmunt","year":"2009","unstructured":"Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454\u20134461","journal-title":"J Clin Oncol"},{"issue":"11","key":"5717_CR3","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, Schutz F, Salhi Y, Winquist E et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850\u20131855","journal-title":"J Clin Oncol"},{"key":"5717_CR4","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/annonc\/mdt007","volume":"24","author":"J Bellmunt","year":"2013","unstructured":"Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y et al (2013) Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 24:1466\u20131472","journal-title":"Ann Oncol"},{"issue":"11","key":"5717_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026","journal-title":"N Engl J Med"},{"key":"5717_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","volume":"21","author":"W Bouleftour","year":"2022","unstructured":"Bouleftour W, Guillot A, Magn\u00e9 N (2022) The anti-nectin 4: a promising tumor cells target. A systematic review. Mol Cancer Ther 21:493\u2013501","journal-title":"Mol Cancer Ther"},{"issue":"e1","key":"5717_CR7","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1136\/bmjspcare-2020-002296","volume":"12","author":"M Cong","year":"2022","unstructured":"Cong M, Song C, Xu H, Song C, Wang C, Fu Z et al (2022) The patient-generated subjective global assessment is a promising screening tool for cancer cachexia. BMJ Support Palliat Care 12(e1):e39\u2013e46","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"5717_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"5717_CR9","unstructured":"Estimated Number of New Cases in 2020, Worldwide, Both Sexes, All Ages. Available online: https:\/\/gco.iarc.fr\/today\/ online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr& sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D= 17&group_cancer=1&include_nmsc=1&include_nmsc_other=1 (Accessed on 25 May 2021)."},{"key":"5717_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","volume":"83","author":"KC Fearon","year":"2006","unstructured":"Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study Group (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345\u20131350","journal-title":"Am J Clin Nutr"},{"key":"5717_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/sj.bjc.6602406","volume":"92","author":"M Hilmy","year":"2005","unstructured":"Hilmy M, Bartlett JM, Underwood MA, McMillan D (2005) The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 92:625\u2013627","journal-title":"Br J Cancer"},{"key":"5717_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-6-75","volume":"6","author":"N Ismaili","year":"2011","unstructured":"Ismaili N (2011) A rare bladder cancer-small cell carcinoma: review and update. Orphanet J Rare Dis 6:75","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"5717_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/cncr.34057","volume":"128","author":"VS Koshkin","year":"2022","unstructured":"Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A et al (2022) Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the urothelial cancer network to investigate therapeutic experiences (UNITE) study. Cancer 128(6):1194\u20131205","journal-title":"Cancer"},{"issue":"13","key":"5717_CR14","doi-asserted-by":"publisher","first-page":"6775","DOI":"10.2147\/CMAR.S318728","volume":"29","author":"XY Liu","year":"2021","unstructured":"Liu XY, Zhang X, Ruan GT, Zhang KP, Tang M, Zhang Q et al (2021) One-year mortality in patients with cancer cachexia: association with albumin and total protein. Cancer Manag Res 29(13):6775\u20136783","journal-title":"Cancer Manag Res"},{"issue":"12","key":"5717_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.890745","volume":"11","author":"CA Liu","year":"2022","unstructured":"Liu CA, Zhang Q, Ruan GT, Shen LY, Xie HL, Liu T et al (2022) Novel diagnostic and prognostic tools for lung cancer cachexia: based on nutritional and inflammatory status. Front Oncol 11(12):890745","journal-title":"Front Oncol"},{"key":"5717_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1373\/clinchem.2007.091959","volume":"54","author":"C Marsik","year":"2008","unstructured":"Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C, Wagner O et al (2008) C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem 54:343\u2013349","journal-title":"Clin Chem"},{"key":"5717_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1017\/S0029665108007131","volume":"67","author":"DC McMillan","year":"2008","unstructured":"McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67:257\u2013262","journal-title":"Proc Nutr Soc"},{"key":"5717_CR18","first-page":"1371","volume":"34","author":"Y Nishio","year":"1988","unstructured":"Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K et al (1988) Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer. Hinyokika Kiyo Acta Urol Jpn 34:1371\u20131375","journal-title":"Hinyokika Kiyo Acta Urol Jpn"},{"issue":"4_suppl","key":"5717_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.2024.42.4_suppl.537","volume":"42","author":"A Nizam","year":"2024","unstructured":"Nizam A, Jindal T, Jiang CY, Alhalabi O, Bakaloudi DR, Talukder R et al (2024) Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. J Clin Oncol 42(4_suppl):537\u2013537. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.537","journal-title":"J Clin Oncol"},{"key":"5717_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","volume":"195","author":"C Oing","year":"2016","unstructured":"Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C (2016) Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond\u2014a comprehensive review of the current literature. J Urol 195:254\u2013263","journal-title":"J Urol"},{"issue":"12","key":"5717_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee J et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125\u20131135","journal-title":"N Engl J Med"},{"key":"5717_CR22","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/S0022-5347(06)00317-X","volume":"175","author":"CG Rogers","year":"2006","unstructured":"Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y et al (2006) Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 175:2048\u20132053","journal-title":"J Urol"},{"issue":"29","key":"5717_CR23","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY et al (2019) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol 37(29):2592\u20132600","journal-title":"J Clin Oncol"},{"key":"5717_CR24","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A (2020) Epidemiology of bladder cancer. Med Sci 8:15","journal-title":"Med Sci"},{"key":"5717_CR25","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068\u20133077","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05717-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05717-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05717-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:04:58Z","timestamp":1716422698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05717-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["5717"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05717-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3952729\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board (IRB) from Osaka Medical and Pharmaceutical University (approval number: RIN-750\u20132571, approved on 24th January 2020). This observational study adhered to ethical principles aligned with the Declaration of Helsinki, the International Conference on Harmonisation's Good Clinical Practice guidelines, Good Pharmacoepidemiology Practices, and relevant laws for noninterventional and observational studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"182"}}